Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

[1]  R. McIntyre,et al.  Asenapine versus olanzapine in acute mania: a double-blind extension study. , 2009, Bipolar disorders.

[2]  R. McIntyre,et al.  A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. , 2009, Bipolar disorders.

[3]  J. Rendell,et al.  Olanzapine in long-term treatment for bipolar disorder. , 2009, The Cochrane database of systematic reviews.

[4]  M. Shahid,et al.  Asenapine: a novel psychopharmacologic agent with a unique human receptor signature , 2009, Journal of psychopharmacology.

[5]  E. Vieta,et al.  Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. , 2008, Bipolar disorders.

[6]  P. Dogterom,et al.  P.3.d.008 Asenapine pharmacokinetics: influence of cytochrome p450 modulators and udp-glucuronyltransferase inhibition , 2008, European Neuropsychopharmacology.

[7]  Craig H Mallinckrodt,et al.  The impact of missing data and how it is handled on the rate of false‐positive results in drug development , 2008, Pharmaceutical statistics.

[8]  E. Vieta,et al.  Acute and long-term treatment of mania , 2008, Dialogues in clinical neuroscience.

[9]  H. Lôo.  [On bipolar disorder]. , 2008, L'Encephale.

[10]  E. Vieta,et al.  Treatment of bipolar disorder: a systematic review of available data and clinical perspectives , 2008 .

[11]  P. Lane.  Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches , 2008, Pharmaceutical statistics.

[12]  R. McIntyre,et al.  Bipolar disorder and suicide: Research synthesis and clinical translation , 2008, Current psychiatry reports.

[13]  D. Gardner,et al.  Monitoring and Management of Metabolic Risk Factors in Outpatients Taking Antipsychotic Drugs: A Controlled Study , 2008, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[14]  S. Potkin,et al.  Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. , 2007, The Journal of clinical psychiatry.

[15]  A. Nyhuis,et al.  Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care. , 2007, Journal of affective disorders.

[16]  A. Lloyd,et al.  Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom , 2007, Journal of psychopharmacology.

[17]  P. Chue,et al.  Do formulation switches exacerbate existing medical illness? Results of an open‐label transition to orally disintegrating risperidone tablets , 2007, Human psychopharmacology.

[18]  A. Young,et al.  The armamentarium of treatments for bipolar disorder: a review of the literature. , 2007, The international journal of neuropsychopharmacology.

[19]  R. Kessler,et al.  Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. , 2007, Archives of general psychiatry.

[20]  W. Rössler,et al.  Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. , 2007, Journal of affective disorders.

[21]  M. Tohen,et al.  Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. , 2006, The Journal of clinical psychiatry.

[22]  T. Ketter,et al.  Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice , 2006, Current medical research and opinion.

[23]  K. Rajagopalan,et al.  The effect of medication adherence on health care utilization in bipolar disorder. , 2006, Managed care interface.

[24]  P. Reeves,et al.  The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. , 2006, Journal of managed care pharmacy : JMCP.

[25]  P. Keck,et al.  Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. , 2006, The Journal of clinical psychiatry.

[26]  G. Sachs,et al.  Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study , 2006, Journal of psychopharmacology.

[27]  J. Ayuso-Mateos,et al.  Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder , 2005, British Journal of Psychiatry.

[28]  L. Judd,et al.  Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. , 2005, Archives of general psychiatry.

[29]  R. McIntyre,et al.  Quetiapine or haloperidol as monotherapy for bipolar mania—a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial , 2005, European Neuropsychopharmacology.

[30]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[31]  S. Potkin,et al.  Ziprasidone in Acute Bipolar Mania: A 21-Day Randomized, Double-Blind, Placebo-Controlled Replication Trial , 2005, Journal of clinical psychopharmacology.

[32]  M. Alda,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. , 2005, Bipolar disorders.

[33]  H. Pincus,et al.  Concomitant pharmacotherapy among youths treated in routine psychiatric practice. , 2005, Journal of child and adolescent psychopharmacology.

[34]  M. Eaddy,et al.  Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. , 2005, Clinical therapeutics.

[35]  J. Newcomer.  Metabolic risk during antipsychotic treatment. , 2004, Clinical therapeutics.

[36]  Simons Wr,et al.  The economic value of lamotrigine as a mood stabilizer: a U.S. managed care perspective. , 2004 .

[37]  C. Bowden.  Making optimal use of combination pharmacotherapy in bipolar disorder. , 2004, The Journal of clinical psychiatry.

[38]  P. Chue,et al.  Acceptability and Disintegration Rates of Orally Disintegrating Risperidone Tablets in Patients with Schizophrenia or Schizoaffective Disorder , 2004, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[39]  P. Keck,et al.  Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. , 2004, The American journal of psychiatry.

[40]  R. McIntyre,et al.  Treating bipolar disorder. Evidence-based guidelines for family medicine. , 2004, Canadian family physician Medecin de famille canadien.

[41]  S. Ahmad,et al.  Value of serum prolactin in the management of syncope , 2004, Emergency Medicine Journal.

[42]  P. Keck,et al.  A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. , 2003, The American journal of psychiatry.

[43]  Larry Alphs,et al.  The InterSePT scale for suicidal thinking reliability and validity , 2003, Schizophrenia Research.

[44]  S. Potkin,et al.  Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. , 2003, The American journal of psychiatry.

[45]  P. Chue,et al.  Dissolution Profile, Tolerability, and Acceptability of the Orally Disintegrating Olanzapine Tablet in Patients with Schizophrenia , 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[46]  P. Sparén,et al.  Excess mortality in bipolar and unipolar disorder in Sweden. , 2001, Archives of general psychiatry.

[47]  M. Tohen,et al.  Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. , 2000, Archives of general psychiatry.

[48]  M. Tohen,et al.  Olanzapine versus placebo in the treatment of acute mania , 1998, European Psychiatry.

[49]  R. C. Young,et al.  A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.

[50]  S. McElroy,et al.  Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. , 2007, Psychopharmacology bulletin.

[51]  R. Baldessarini,et al.  Suicidal Behaviour in Bipolar Disorder , 2003, CNS drugs.

[52]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[53]  T. Hergueta,et al.  The mini international neuropsychiatric interview , 1998, European Psychiatry.

[54]  S M Montgomery,et al.  Depressive symptoms in acute schizophrenia. , 1979, Progress in neuro-psychopharmacology.